The study assessed the vaccines’ ability to provide protection against infection, including asymptomatic ones. Credit: Marco Verch Professional Photographer / Flickr.

A real-world study by the US Centers for Disease Control and Prevention (CDC) has revealed that the mRNA Covid-19 vaccines developed by Pfizer with BioNTech and Moderna reduced the risk of infection by 80% two weeks or more after administering the first of two shots.

In the study with 3,950 participants in six states over a 13-week period from 14 December 2020 to 13 March 2021, the risk of infection decreased 90% by two weeks after the second shot.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The latest findings are consistent with those from phase III trials conducted with the Covid-19 vaccines before they received Emergency Use Authorizations (EUA) from the US Food and Drug Administration (FDA).

Part of the study was assessing the vaccines’ ability to provide protection against infection, including asymptomatic ones.

CDC director Rochelle Walensky said: “The authorised mRNA Covid-19 vaccines provided early, substantial real-world protection against infection for our nation’s healthcare personnel, first responders and other frontline essential workers.”

On another note, GSK has entered an agreement to support the manufacturing of up to 60 million doses of Novavax’ protein-based Covid-19 vaccine candidate NVX-CoV2373 for use in the UK.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company signed the agreement with Novavax and the UK Government Vaccines Taskforce (VTF).

On concluding the technology transfer between the two companies, GSK will extend the ‘fill and finish’ manufacturing capacity at its Barnard Castle facility in north-east England starting as early as May.

UK Prime Minister Boris Johnson said: “We remain on track to offer the first jab to all over 50s by 15 April and all adults by the end of July, and I want to once again encourage everyone to come forward for a vaccine when you’re called.”

In February, multiple regulatory authorities started the rolling review process for the authorisation of Novavax’s Covid-19 vaccine.

Meanwhile, the Republic of the Philippines’ Department of Health, Food and Drug Administration (Philippines FDA) has approved the use of Cytodyn’s Vyrologix (leronlimab-PRO 140) for treating a Covid-19 patient under Compassionate Special Permit (CSP) under the FDA Order No. 2016-005.